Dietary oxalate and calcium oxalate nephrolithiasis.
OBJECTIVE
Patients with calcium oxalate kidney stones are advised to decrease the consumption of foods that contain oxalate. We hypothesized that a cutback in dietary oxalate would lead to a decrease in the urinary excretion of oxalate and decreased stone recurrence. We tested the hypothesis in an animal model of calcium oxalate nephrolithiasis.


METHODS
Hydroxy-L-proline (5%), a precursor of oxalate found in collagenous foods, was given with rat chow to male Sprague-Dawley rats. After 42 days rats in group 1 continued on hydroxy-L-proline, while those in group 2 were given chow without added hydroxy-L-proline for the next 21 days. Food and water consumption as well as weight were monitored regularly. Once weekly urine was collected and analyzed for creatinine, calcium, oxalate, lactate dehydrogenase, 8-isoprostane and H(2)O(2). Urinary pH and crystalluria were monitored. Rats were sacrificed at 28, 42 and 63 days, respectively. Renal tissue was examined for crystal deposition by light microscopy.


RESULTS
Rats receiving hydroxy-L-proline showed hyperoxaluria, calcium oxalate crystalluria and nephrolithiasis, and by day 42 all contained renal calcium oxalate crystal deposits. Urinary excretion of lactate dehydrogenase, 8-isoprostane and H(2)O(2) increased significantly. After hydroxy-L-proline was discontinued in group 2 there was a significant decrease in urinary oxalate, 8-isoprostane and H(2)O(2). Half of the group 2 rats appeared to be crystal-free.


CONCLUSIONS
Dietary sources of oxalate can induce hyperoxaluria and crystal deposition in the kidneys with associated degradation in renal biology. Eliminating oxalate from the diet decreases not only urinary oxalate, but also calcium oxalate crystal deposits in the kidneys and improves their function.
Khan
Saeed R
SR
Department of Pathology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, Florida 32610-0275, USA. Khan@pathology.ufl.edu
Glenton
Patricia A
PA
Byer
Karen J
KJ
D000818:Animals; D002129:Calcium Oxalate / Q000493:pharmacokinetics / Q000633:toxicity*; D003404:Creatinine / Q000652:urine; D019587:Dietary Supplements / Q000633:toxicity*; D004195:Disease Models, Animal; D005500:Follow-Up Studies; D006863:Hydrogen-Ion Concentration; D006909:Hydroxyproline / Q000493:pharmacokinetics / Q000633:toxicity*; D006959:Hyperoxaluria / Q000139:chemically induced / Q000652:urine; D007668:Kidney / Q000648:ultrastructure; D008297:Male; D008855:Microscopy, Electron, Scanning; D053040:Nephrolithiasis / Q000139:chemically induced / Q000652:urine*; D051381:Rats; D017207:Rats, Sprague-Dawley; D014556:Urine / Q000737:chemistry
D002129:Calcium Oxalate; D003404:Creatinine; D006909:Hydroxyproline